News
Melbourne biotech Mesoblast (ASX:MSB) is attempting to commercialise a stem cell treatment known as remestemcel-L for conditions such as acute graft versus host disease, advanced heart failure and chronic lower back pain due to degenerative disc disease. Mesoblast acquired remestemcel-L from US-based Osiris Therapeutics in 2013.
Mesoblast’s proprietary process selects precursors and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell bank is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5 billion in 2011. The company dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The company was dealt a blow in October 2020 when the US Food and Drug Administration declined to approve remestemcel-L for the treatment of acute graft versus host disease in children, instead asking for more data. Mesoblast is expected to dispute the FDA’s decision.
Mesoblast licensed remestemcel-L to Swiss pharmaceutical giant Novartis in November 2020 for indications other than graft versus host disease, a devastating complication from bone marrow transplants.
RELATED STOCKHEAD STORIES
News
Here are the top ASX large cap movers for Tuesday
News
Closing Bell: ASX trades flat as two battery metal stocks return from ASX purgatory
News
Here are the top ASX large cap movers for Wednesday
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
Here are the ASX heart stocks fighting the number one killer disease in humans
Health & Biotech
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child
Health & Biotech
Mesoblast and the ASX’s other big biotechs have intrigued investors this year; here’s what’s in store next
News
Here are the top ASX large cap movers for Monday
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
News
ASX Meme Stocks: Just how have they turned out for investors who took the plunge?
News
Here are the top ASX large cap movers for Tuesday
Health & Biotech
ASX Health Stocks: Beamtree gets on the M&A trail while Creso Pharma eyes NASDAQ listing
Health & Biotech
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit
Health & Biotech
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
Health & Biotech
Investors have struggled to find long term money makers from COVID, but has this sector been the one all along?
Health & Biotech
Mesoblast says its stem cell treatment saved lives of severely ill COVID patients
Health & Biotech